News Jasper Therapeutics, Inc.

Equities

JSPR

US4718712023

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
20.4 ^USD	-3.68%		-9.41%	+158.56%

Apr. 03	Evercore ISI Initiates Jasper Therapeutics With Outperform Rating, Price Target is $65	MT
Mar. 28	Jasper Therapeutics Initiated at Outperform, Speculative Risk by RBC, Price Target Set at $70 Amid Bullish View on Lead Asset	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Jasper Therapeutics : Corporate Presentation April 2024	Apr. 16	PU
Evercore ISI Initiates Jasper Therapeutics With Outperform Rating, Price Target is $65	Apr. 03	MT
Jasper Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference	Apr. 02	AQ
Jasper Therapeutics Initiated at Outperform, Speculative Risk by RBC, Price Target Set at $70 Amid Bullish View on Lead Asset	Mar. 28	MT
Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference	Mar. 21	AQ
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria	Mar. 19	AQ
Jasper Therapeutics, Inc. Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria	Mar. 19	CI
TD Cowen Initiates Jasper Therapeutics With Outperform Rating	Mar. 18	MT
New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia	Mar. 15	AQ
Jasper Therapeutics, Inc. Announces Additional Positive Phase 1b/2a Data on Briquilimab as A Conditioning Agent in the Treatment of Fanconi Anemia	Mar. 15	CI
Jasper Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 04	CI
Jasper Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 04	CI
Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments	Mar. 04	AQ
Jasper Therapeutics : Corporate Presentation March 2024	Mar. 04	PU
Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference	Feb. 26	AQ
Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology Annual Meeting	Feb. 26	AQ
Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting	Feb. 23	AQ
Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference	Feb. 07	AQ
Jasper Therapeutics Prices $50 Million Common Stock Offering -- Shares Rise	Feb. 06	MT
Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock	Feb. 06	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Jasper Therapeutics, Inc.

Equities

JSPR

US4718712023

Summary

Filters